Ivabradina Viatris

Ivabradine, the active ingredient in Ivabradina Viatris, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used in chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivabradina Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Viatris is used in cardiovascular conditions that involve elevated heart rate.

- Chronic stable angina pectoris: improves exercise tolerance by lowering heart rate without affecting myocardial contractility. - Heart failure with reduced ejection fraction (HFrEF): decreases hospitalization risk by reducing heart rate in patients already receiving guideline‑directed therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate falls below the intended range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - High‑grade atrioventricular block. - Persistent visual impairment. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors.

- Dose adjustment: reduce dose in patients with moderate hepatic impairment. - Monitor heart rate: avoid use if resting heart rate is <60 bpm. - Avoid concomitant strong CYP3A4 inhibitors: may increase ivabradine exposure. - Caution in sick‑sinus syndrome or atrioventricular block: may exacerbate bradyarrhythmias. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradina Viatris may interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): increase plasma levels. - Co‑administration with other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Diltiazem or verapamil: potentiate bradycardia via CYP3A4 inhibition.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Certain antidepressants that affect autonomic tone (e.g., SSRIs): monitor heart rate. - Loop or thiazide diuretics: watch for electrolyte shifts that could influence cardiac conduction.